216 related articles for article (PubMed ID: 31896137)
1. EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms.
Munker S; Vogelhuber M; Bornschein J; Stroszczynski C; Evert M; Schlitt H; Herr W; Teufel A
Z Gastroenterol; 2020 Feb; 58(2):133-136. PubMed ID: 31896137
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
4. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
5. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
[TBL] [Abstract][Full Text] [Related]
6. Current standards of care in small-cell and non-small-cell lung cancer.
Schiller JH
Oncology; 2001; 61 Suppl 1():3-13. PubMed ID: 11598409
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.
White SC; Lorigan P; Middleton MR; Anderson H; Valle J; Summers Y; Burt PA; Arance A; Stout R; Thatcher N
Cancer; 2001 Aug; 92(3):601-8. PubMed ID: 11505405
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
10. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
Holmager P; Langer SW; Kjaer A; Ringholm L; Garbyal RS; Pommergaard HC; Hansen CP; Federspiel B; Andreassen M; Knigge U
Curr Treat Options Oncol; 2022 Jun; 23(6):806-817. PubMed ID: 35362798
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
[TBL] [Abstract][Full Text] [Related]
12. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
Gervais R; Le Caer H; Monnet I; Falchero L; Baize N; Olivero G; Thomas P; Berard H; Auliac JB; Chouaid C;
Clin Lung Cancer; 2015 Mar; 16(2):100-5. PubMed ID: 25467927
[TBL] [Abstract][Full Text] [Related]
13. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer.
Comis RL
Semin Oncol; 1986 Sep; 13(3 Suppl 3):40-4. PubMed ID: 3020699
[TBL] [Abstract][Full Text] [Related]
15. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control.
Videtic GM; Fung K; Tomiak AT; Stitt LW; Dar AR; Truong PT; Yu EW; Vincent MD; Kocha WI
Lung Cancer; 2001; 33(2-3):249-58. PubMed ID: 11551420
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
17. A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer.
Erkişi M; Unsal M; Tunali C; Burgut R; Doran F
J Chemother; 1993 Feb; 5(1):56-9. PubMed ID: 8384659
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.
Bunn PA; Greco FA; Einhorn L
Semin Oncol; 1986 Sep; 13(3 Suppl 3):45-53. PubMed ID: 3020700
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
